ThromboGenics NV and BioInvent International

ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402

Older News

LEUVEN, Belgium and LUND, Sweden - ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy